825 8th Avenue
New York, NY 10019


Jurisdictions:

United States

Practice areas:

General Patent Litigation
Hatch-Waxman Patent Litigation


Evan R. Chesler

Cravath, Swaine & Moore LLP

Worldwide Plaza
825 8th Avenue
New York, NY 10019
T: +1 212 474 1243
echesler@cravath.com
www.cravath.com

Evan R. Chesler is Cravath, Swaine & Moore LLP's Chairman. One of the most highly regarded litigators in the United States, Mr. Chesler has extensive experience handling trials, arbitrations and appeals in a wide variety of matters, including intellectual property, for clients in virtually every industry. He has achieved numerous successes for major life sciences companies in "bet-the-brand" litigation over valuable patent rights.

Mr. Chesler currently represents Novartis Pharmaceuticals in litigation arising under the False Claims Act as well as in antitrust litigation alleging that the company entered into an unlawful agreement with Par Pharmaceuticals which was intended to delay generic competition for Exforge®, a branded prescription drug.

Mr. Chesler recently represented Merck Sharp & Dohme as plaintiff in three separate patent infringement actions concerning its antifungal agent Noxafil®. He secured a trial victory in one suit upholding the validity of Merck's patent and the other actions settled. Mr. Chesler also represented Mylan in winning both a judgment after trial upholding the validity of its patents on respiratory drug Perforomist® and a Federal Circuit Court of Appeals decision concerning the validity of pharmaceutical composition patents covering the drug. He obtained a Federal Circuit decision (following appeal to the Supreme Court) invalidating certain patent claims asserted against Mylan's generic version of the multiple sclerosis drug Copaxone®.

Mr. Chesler's other life sciences representations include winning a validity challenge for Novartis after a jury trial in its patent infringement suit against Teva Pharmaceuticals relating to the antiviral drug Famvir® and securing damages of over $442 million for Bristol-Myers Squibb and Sanofi-Aventis in patent infringement litigation against Apotex regarding Plavix®.

Mr. Chesler received an A.B. in History from New York University, an M.A. in Russian Area Studies from Hunter College and a J.D. from New York University School of Law. He previously served as Cravath's head of litigation, deputy presiding partner and presiding partner.